Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients

Francesca Colapietro, Giovanni Angelotti, Chiara Masetti, Dana Shiffer, Nicola Pugliese, Stella De Nicola, F. Carella, Antonio Desai, Monica Ormas, Marta Calatroni, Paolo Omodei, Michele Ciccarelli, Stefano Aliberti, Francesco Reggiani, Michele Bartoletti, Maurizio Cecconi, Ana Lleò, Alessio Aghemo, Antonio VozaViruses 2023 · DOI

TL;DR

This study investigated whether Ursodeoxycholic Acid (UDCA), a bile acid with potential antiviral properties, improves outcomes in hospitalized COVID-19 patients. While UDCA did not significantly impact overall mortality, it was associated with a reduced need for CPAP treatment, suggesting a potential benefit in managing respiratory distress.

What Problem Does This Paper Address?

The COVID-19 pandemic has spurred a continuous search for effective treatments, especially for hospitalized patients. While vaccines and antivirals exist, challenges remain, including emerging variants, varying vaccine efficacy in at-risk groups, and limitations of current antiviral drugs (e.g., cost, administration routes, drug interactions). Ursodeoxycholic acid (UDCA), a well-established drug for cholestatic liver diseases, has shown promise in in vitro and some limited in vivo studies for reducing SARS-CoV-2 susceptibility and improving infection outcomes, particularly in patients with liver conditions. However, robust real-world evidence on its efficacy in a broader hospitalized COVID-19 population was lacking. This paper aims to fill that gap by evaluating UDCA's impact on mortality and respiratory support needs in a large cohort of hospitalized COVID-19 patients.

Methods

This was a retrospective, single-center, observational case-control study. The researchers identified patients hospitalized with COVID-19 between January 2020 and January 2023. The "UDCA group" consisted of patients receiving therapeutic doses of UDCA for at least three months prior to admission, with indications including cholelithiasis, cholestatic liver diseases, or bone marrow diseases. This group was compared to a "control group" of patients not receiving UDCA.

Key outcomes assessed were in-hospital mortality and the need for Continuous Positive Airway Pressure (CPAP) treatment, either at admission or during hospitalization. Statistical analysis involved class-weighted logistic regression to account for sample imbalances, with a 10-fold nested stratified cross-validation for model evaluation.

Datasets

The study utilized data from the electronic health records (EHR) of 3847 patients consecutively hospitalized for COVID-19 at Humanitas Research Hospital (Milan, Italy) between January 2020 and January 2023. The dataset included demographic information, comorbidities (e.g., hypertension, diabetes, CKD, liver disease, neoplasia), COVID-19 vaccination status, and biochemical data (LFTs, platelet count).

Key Insights and Ideas

  • UDCA's potential benefit might be nuanced: While initial in vitro and small cohort studies suggested broader benefits, this larger real-world study indicates UDCA may not be a "magic bullet" for overall mortality in hospitalized COVID-19 patients.
  • Respiratory support is a potential area of impact: The finding of a reduced need for CPAP treatment in the UDCA group is intriguing. This suggests UDCA might play a role in mitigating the severe respiratory complications of COVID-19, even if it doesn't prevent death.
  • Comorbidity profile matters: The UDCA group had a higher prevalence of liver diseases and was more likely to be vaccinated, which are important factors to consider when interpreting the results. The study acknowledges these differences and attempts to account for them statistically.
  • Real-world evidence is crucial: This study highlights the importance of moving beyond in vitro findings and small patient groups to assess the efficacy of potential treatments in diverse, real-world clinical settings.

Key Results

  • Mortality: Overall in-hospital mortality was similar between the UDCA group (22.8%) and the control group (21.3%), with a p-value of 0.243, indicating no statistically significant difference.
  • CPAP Treatment: The UDCA group showed a statistically significant lower rate of CPAP treatment (15.7%) compared to the control group (25.9%). The odds ratio for UDCA treatment reducing CPAP need was 0.76 (p < 0.05).
  • Comorbidities: While diabetes and neoplasia rates were similar between groups, the UDCA group had a higher prevalence of liver diseases (14.0% vs. 2.5%) and COVID-19 vaccination (54.4% vs. 30.2%).
  • UDCA as a predictor: UDCA treatment was not found to be an independent predictor of survival in hospitalized COVID-19 patients.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small UDCA proportion: The UDCA group represented only 1.5% of the total cohort, which prevented the use of propensity score matching for a more robust comparison.
  • Retrospective design: Information on the duration of UDCA treatment could not be retrieved, limiting the ability to correlate treatment duration with outcomes.
  • Confounding factors: The widespread implementation of COVID-19 vaccination during the study period likely impacted outcomes. The authors also note that the lower CPAP rate in patients with concurrent neoplastic diseases might reflect clinical judgment or a less aggressive treatment approach.

Future work suggested by the authors includes focusing on patients with less severe disease or exploring combinations of UDCA with other approved regimens, given the lack of significant drug-drug interactions. Further research could also investigate the specific mechanisms by which UDCA might influence respiratory distress.

Summary updated

Abstract

Ursodeoxycholic acid (UDCA) was demonstrated to reduce susceptibility to SARS-CoV-2 infection in vitro and improve infection course in chronic liver diseases. However, real-life evidence is lacking. We analyzed the impact of UDCA on COVID-19 outcomes in patients hospitalized in a tertiary center. Between January 2020 and January 2023, among 3847 patients consecutively hospitalized for COVID19, 57 (=UDCA group) were taking UDCA. The UDCA and the control groups (<i>n</i> = 3790) did not differ concerning comorbidities including diabetes mellitus type 2 (15.8% vs. 12.8%) and neoplasia (12.3% vs. 9.4%). Liver diseases and vaccination rate were more common in the UDCA group (14.0% vs. 2.5% and 54.4% vs. 30.2%, respectively). Overall mortality and CPAP treatment were 22.8 % and 15.7% in the UDCA, and 21.3% and 25.9% in the control group. Mortality was similar (<i>p</i> = 0.243), whereas UDCA was associated with a lower rate of CPAP treatment (OR = 0.76, <i>p</i> < 0.05). Treatment with UDCA was not an independent predictor of survival in patients hospitalized for COVID-19.
BibTeX
@inproceedings{colapietro2023ursodeoxycholic,
  author = {Francesca Colapietro and Giovanni Angelotti and Chiara Masetti and Dana Shiffer and Nicola Pugliese and Stella De Nicola and F. Carella and Antonio Desai and Monica Ormas and Marta Calatroni and Paolo Omodei and Michele Ciccarelli and Stefano Aliberti and Francesco Reggiani and Michele Bartoletti and Maurizio Cecconi and Ana Lleò and Alessio Aghemo and Antonio Voza},
  title = {{Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients}},
  booktitle = {Viruses},
  year = {2023},
  doi = {10.3390/v15081738},
}
Figure